CLAIMS

1. Use of a composition comprising a cyclodextrin compound and budesonide or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing neutrophilic inflamantion in a patient suffering from pulmonary inflammatory disease.

2. Use according to Claim 1, in which the cyclodextrin compound when administered delivers the budesonide in a dosage range of from 0.1 to 500 mcg per day.

3. Use according to Claim 1 or 2, in which the cyclodextrin compound when administered delivers the budesonide in a dosage range of from 50 to 200 mcg per day.

4. Use according to Claim 1, 2 or 3, in which the molar ratio between the budesonide and the cyclodextrin compound is from 1:1 to 1:100.

5. Use according to any preceding claim, in which the cyclodextrin compound is hydroxypropyl β-cyclodextrin.

6. Use according to Claim 5, in which the medicament comprises 250 µg/ml budesonide and 20 mM HP-β-CD.

7. Use according to Claim 5, in which the medicament comprises 100 µg/ml budesonide and 20 mM HP-β-CD.

8. Use according to Claim 5, in which the medicament comprises 250 µg/ml budesonide and 10 mM HP-β-CD.

9. Use according to Claim 5, in which the medicament comprises 100 µg/ml budesonide and 10 mM HP-β-CD.

10. Use according to Claim 5, in which the medicament is for delivering the budesonide derivative in a dosage range of from 50 to 200 mcg per day.

11. Use according to any preceding claim, in which the medicament comprises a solution having a pH of from 7 to 7.5.

12. Use according to Claim 1 or 5, in which the medicament comprises a complex of a budesonide derivative and a cyclodextrin compound in a stoichiometric ratio of 1:1.

13. Use according to any preceding claim, in which the medicament is capable of decreasing CXCL-1 levels in a host mammal.

14. Use according to any preceding claim, in which the pulmonary inflammatory disease is chronic obstructive pulmonary disease.